ST Notch announced that in the first half of 2026, it achieved revenue of 1,140 billion yuan, an increase of 8.72% over the previous year. The oligonucleotide API production workshop at the Lianyungang factory was officially put into operation, and the oligonucleotide production capacity jumped to tonnage; the small-volume injection production line passed the drug GMP compliance inspection. The 2025 annual equity distribution was implemented during the reporting period, with a cash dividend of 0.35 yuan per share based on a total share capital of 31605,1897 shares, for a total of 111 million yuan, accounting for 33.28% of the net profit due to mother in 2025. In June 2026, the third phase of restricted stock ownership was completed, and 764,400 shares were vested to 58 incentive recipients.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.